Document:

EX-10.30

 Exhibit 10.30 

EXECUTION VERSION 

COMMON STOCK PURCHASE AGREEMENT 

THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 30th day of April, 2018 by and between NantCell, Inc., a
Delaware corporation (the “Company”), and NantBio, Inc. (formerly named NantBioScience, Inc.), a Delaware corporation (the “Purchaser”). Certain capitalized terms used in this Agreement without definition shall be construed to
have the meanings set forth or referenced in Section 1.3. 
 WHEREAS, the Company has borrowed an aggregate of $98,029,281.92 from the
Purchaser pursuant to a Demand Promissory Note dated January 31, 2016 (the “Promissory Note”); 
 WHEREAS, as of the date of
this Agreement, the Company owes the Purchaser an aggregate of $102,361,584.95 under the Promissory Note, which amount includes accrued interest through the date hereof; and 

WHEREAS, the Purchaser is interested in acquiring certain voting securities of the Company, solely for the purpose of investment, with no
intention of participating in the formulation, determination or direction of the basic business decisions of the Company (such acquisition of securities to be paid for by the cancellation of indebtedness under the Promissory Note); 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 1. Purchase and Sale of Stock. 

1.1. Sale and Issuance of Stock. 

(a) The Company previously adopted and filed with the Secretary of State of the State of Delaware the Amended and Restated Certificate of
Incorporation attached hereto as Exhibit A (the “Restated Certificate”). 
 (b) Subject to the terms and conditions of this
Agreement, the Purchaser agrees to purchase at the Closing and the Company agrees to sell and issue to the Purchaser at the Closing 10,236,159 shares of Common Stock, $0.001 par value per share (the “Common Stock”), at a purchase price of
$10.00 per share, for an aggregate purchase price of One Hundred Two Million Three Hundred Sixty One Thousand Five Hundred Ninety Dollars ($102,361,590). The parties acknowledge and agree that the foregoing purchase price will be satisfied through
the cancellation of all indebtedness under the Promissory Note. 
 1.2. Closing; Delivery. 

(a) The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures, at 10:00 a.m. Pacific time, on
the date of this Agreement, or at such other time as the Company and the Purchaser mutually agree upon, orally or in writing (which time and place are designated as the “Closing”). 

  
 1 

 (b) At the Closing: 

(i) the Company shall deliver to the Purchaser a certificate representing the Common Stock being purchased by the Purchaser at
the Closing; 
 (ii) the Company and the Purchaser shall execute and deliver the Investors’ Rights Agreement and the
Right of First Refusal and Co-Sale Agreement; and 
 (iii) the Purchaser shall surrender to the Company for cancellation at
the Closing the Promissory Note. For the avoidance of doubt, the parties acknowledge and agree that the cancellation of the Promissory Note satisfies in full the payment of the Shares (and the Company shall not owe any further amounts to the
Purchaser under the Promissory Note). 
 Each of the closing deliverables shall be deemed to have been delivered simultaneously at the Closing and no
deliverable shall be deemed to have been delivered until all deliverables have been delivered. 
 1.3. Defined Terms Used in this
Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below. 

(a) “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled
by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general
partners or managing members of, or shares the same management company with, such Person. 
 (b) “Governmental Entity” means any
court, regulatory or administrative agency or commission or other federal, state, county, local or other foreign governmental authority, instrumentality, agency or commission or quasi-public legal authority. 

(c) “Investors’ Rights Agreement” means the agreement between the Company and the Purchaser, dated as of the date of the
Closing, in the form of Exhibit B attached to this Agreement. 
 (d) “Knowledge,” including the phrase “to the
Company’s knowledge,” shall mean the actual knowledge of Patrick Soon-Shiong, Charles Kim and Shahrooz Rabizadeh. 
 (e)
“Parties” means the Company and the Purchaser. 
 (f) “Person” means any individual, corporation, partnership, trust,
limited liability company, association or other entity. 

  
 2 

 (g) “Right of First Refusal and Co-Sale Agreement” means the agreement among the
Company and the Purchaser, dated as of the date of the Closing, in the form of Exhibit C attached to this Agreement. 
 (h)
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 
 (i)
“Shares” means the shares of Common Stock issued at the Closing. 
 (j) “Transaction Agreements” means this Agreement,
the Investors’ Rights Agreement and the Right of First Refusal and Co-Sale Agreement. 
 2. Representations and Warranties of the
Company. The Company hereby represent and warrant to the Purchaser that the following representations are true and complete as of the date of this Agreement and the date of the Closing, except as otherwise indicated. 

2.1. Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and is
in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property or results of operations of the Company.

 2.2. Capitalization. 

(a) The capitalization of the Company is as set forth on Exhibit D attached hereto. All of the outstanding shares of Common Stock have been
duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. The rights, privileges and preferences of the Common Stock are as stated in the Restated Certificate and as
provided by the Delaware General Corporation Law. 
 (b) Except as set forth on Exhibit D and for the rights provided in
Section 3.3 of the Investors’ Rights Agreement, there are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase
or acquire from the Company any shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock. 

(c) The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by this Agreement. The
Company is not a party or subject to any agreement or understanding, and to the Company’s knowledge, there is no agreement or understanding between any Persons that affects or relates to the voting or giving of written consents with respect to
any security or by a director of the Company. 
 2.3. Authorization. All corporate action required to be taken by the Board of
Directors and equity holders of the Company in order to authorize the Company to enter into the Transaction Agreements and perform its obligations thereunder, and to issue the Shares at the Closing, has been taken or will be taken prior to the
Closing. All action on the part of the 

  
 3 

 
officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Company to be performed as of the Closing, and the
issuance and delivery of the Shares has been taken or will be taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Company shall constitute valid and legally binding obligations of the Company, enforceable
against it in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the
Investors’ Rights Agreement may be limited by applicable federal or state securities laws. 
 2.4. Valid Issuance of Shares. The
Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer
under the Investor Rights Agreement and Right of First Refusal and Co-Sale Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the
Purchaser in Section 3 of this Agreement and subject to the filings described in Section 2.5 below, the Shares will be issued in compliance with all applicable federal and state securities laws. 

2.5. Governmental Consents and Filings. Assuming the accuracy of the representations made by the Purchaser in Section 3 of
this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with
the consummation of the transactions contemplated by this Agreement, except for filings pursuant to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner. 

2.6. Litigation. Except with respect to the Company’s acquisition of Altor BioScience Corporation and except with respect to the
lawsuit involving Precision Biologics Inc., there is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to the Company’s knowledge, currently threatened (i) against the Company or any officer or
director of the Company (in the case of officers and directors such as would affect the Company); (ii) that questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to consummate the transactions
contemplated by the Transaction Agreements; or (iii) to the Company’s knowledge, that would reasonably be expected to have, either individually or in the aggregate, a material adverse effect on the business, assets, liabilities, financial
condition, property or results of operations of the Company. Neither the Company nor, to the Company’s knowledge, any of its officers or directors is a party or is named as subject to the provisions of any order, writ, injunction, judgment or
decree of any court or government agency or instrumentality such as would affect the Company. 
 2.7. Intellectual Property. The
Company owns or has a valid right to use all patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works, proprietary rights and processes necessary for its business as now conducted and as proposed to be conducted and, to
the Company’s knowledge, without any conflict or infringement of the 

  
 4 

 
rights of any other Person. Neither the Company or any of its Affiliates has received any communications alleging that the Company or its Affiliates has violated or, by conducting its business,
would violate any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person, such as would affect the Company. To the knowledge of the Company, it will
not be necessary to use any inventions of any of its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Company, such as would affect the Company. 

2.8. Compliance with Other Instruments. The Company is not in violation or default (i) of any provisions of its Restated
Certificate or Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any agreement or contract to which it is a party or by which it is bound, or, to its knowledge, of any provision of federal or state statute, rule
or regulation applicable to the Company, except in the case of clause (iii) the violation of which would not have a material adverse effect on the business, assets, liabilities, financial condition, property or results of operations of the
Company. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation by any of the Company or be in conflict with or
constitute, with or without the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement by any of the Company such as would affect the Company or
(ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company. 

2.9. Financial Statements. The Company has delivered to the Purchaser for the Company and its subsidiaries (i) a unaudited
consolidated balance sheet as of December 31, 2017 and (ii) a unaudited consolidated income statement for the fiscal year ended December 31, 2017 (collectively, the “Financial Statements”). The Financial Statements
have been prepared on a consistent basis throughout the periods indicated, accurately reflect the books, records and accounts of the Company and its subsidiaries and fairly present in all material respects the consolidated financial condition and
operating results of the Company and its subsidiaries as of the dates, and for the periods, indicated therein, subject in each case to exceptions set forth on Exhibit E. Except as set forth in the Financial Statements, none of the Company nor
any of its subsidiaries has any material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to December 31, 2017, (ii) obligations under contracts and
commitments with customers and suppliers incurred in the ordinary course of business (and that are not in the nature of and do not arise out of a default or breach), (iii) liabilities and obligations of a type or nature not required under
generally accepted accounting principles to be reflected in the Financial Statements and (iv) those liabilities that would not individually or in the aggregate reasonably be expected to have a material adverse effect on the business, assets,
liabilities, financial condition, property or results of operations of the Company. 
 2.10. Tax Returns and Payments. There are no
federal, state, county, local or foreign taxes dues and payable by the Company which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company which are due,

  
 5 

 
whether or not assessed or disputed. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it. 

2.11. Corporate Documents. The Restated Certificate and Bylaws of the Company are in the form provided to the Purchaser. The Company is
not in violation of any provisions of its Restated Certificate or Bylaws. 
 2.12. Disclosure. The Company has made available to the
Purchaser all the information reasonably available to the Company that the Purchaser has requested for deciding whether to acquire the Shares. No representation or warranty of the Company contained in this Agreement, and no certificate furnished or
to be furnished to the Purchaser at the Closing contains any untrue statement of a material fact or to the Company’s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading
in light of the circumstances under which they were made. 
 2.13. Disclaimer. Notwithstanding anything to the contrary contained in
this Agreement, neither the Company nor any of its subsidiaries nor any of their respective Affiliates or representatives has made, or shall be deemed to have made, to the Purchaser or any other Person any representations or warranties other than
those expressly made by the Company in this Section 2 and Section 6.7. 
 3. Representations and Warranties of
the Purchaser. The Purchaser hereby represents and warrants to the Company that: 
 3 .1. Authorization. The Purchaser has full
power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser,
enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights
generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be
limited by applicable federal or state securities laws. 
 3.2. Governmental Consents and Filings. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation of the transactions
contemplated by this Agreement. 
 3.3. Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon
the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by the Purchaser will be acquired for investment for the Purchaser’s
own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By
executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any 

  
 6 

 
Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. 

3.4. Restricted Securities. The Purchaser understands that the Shares have not been, and will not be, registered under the Securities
Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed
herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Shares indefinitely unless they are
registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register
or qualify the Shares for resale except as set forth in the Investors’ Rights Agreement. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be
able to satisfy. 
 3.5. No Public Market. The Purchaser understands that no public market now exists for the Shares, and that the
Company has made no assurances that a public market will ever exist for the Shares. 
 3.6. Legends. The Purchaser understands that
the Shares and any securities issued in respect of or exchange for the Shares, may bear one or all of the following legends: 
 (a)
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY
BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

(b) Any legend set forth in, or required by, the other Transaction Agreements. 

(c) Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the
certificate so legended. 
 3.7. Accredited Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation
D promulgated under the Securities Act. 
 3.8. Disclaimer. Notwithstanding anything to the contrary contained in this Agreement,
neither the Purchaser nor any of its subsidiaries nor any of their respective Affiliates or representatives has made, or shall be deemed to have made, to the Company or any other 

  
 7 

 
Person any representations or warranties other than those expressly made by the Purchaser in this Section 3 and Section 6. 7. 

4. Conditions to the Purchaser’s Obligations at Closing. The obligations of the Purchaser to purchase Shares at the Closing are
subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived: 
 4.1.
Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct in all respects as of such Closing. 

4.2. Performance. The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in
this Agreement that are required to be performed or complied with by the Company on or before such Closing. 
 4.3. Transaction
Agreements. The Transaction Agreements shall have been executed and delivered by the parties thereto. 
 4.4. Qualifications. All
authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be
obtained and effective as of such Closing. 
 4.5. Proceedings and Documents. All corporate and other proceedings in connection with
the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to the Purchaser, and the Purchaser (or its counsel) shall have received all such counterpart original and
certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates. 
 5.
Conditions of the Company’s Obligations at Closing. The obligations of the Company to sell Shares to the Purchaser at the Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless
otherwise waived: 
 5.1. Representations and Warranties. The representations and warranties of the Purchaser contained in
Section 3 shall be true and correct in all respects as of such Closing. 
 5.2. Performance. The Purchaser shall have
performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 

5.3. Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United
States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of the Closing. 

5.4. Transaction Agreements. The Transaction Agreements shall have been executed and delivered by the parties thereto. 

6. Miscellaneous. 

  
 8 

 6.1. Survival of Warranties. Unless otherwise set forth in this Agreement, the
representations and warranties of the Company and the Purchaser contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or
knowledge of the subject matter thereof made by or on behalf of the Purchaser or the Company. 
 6.2. Successors and Assigns. The
terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Celgene may assign this Agreement to one or more of its
affiliates. 
 6.3. Governing Law. This Agreement shall be governed by the internal law of the State of Delaware. 

6.4. Countemarts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes. 
 6.5. Titles and Subtitles. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.6. Notices. All notices
and other communications given or made pursuant to this Agreement shall, unless otherwise explicitly provided herein, be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (a) personal delivery to the party
to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or to such e-mail address, facsimile number or address as subsequently modified by written notice given in
accordance with this Section 6.6. 
 6.7. No Finder’s Fees. Each party represents that it neither is nor will be
obligated for any finder’s fee or commission in connection with this transaction. The Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s or
broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees, or representatives is responsible. The Company agrees
to indemnify and hold harmless the Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability
or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

  
 9 

 6.8. Attorneys’ Fees. If any action at law or in equity (including arbitration)
is necessary to enforce or interpret the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may
be entitled. 
 6.9. Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written
consent of the Company and the Purchaser. Any amendment or waiver effected in accordance with this Section 6.9 shall be binding upon the Purchaser and each transferee of the Shares, each future holder of all such securities, and the
Company. 
 6.1 0. Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. 
 6.11. Delays or Omissions. No delay or omission to exercise any right, power or remedy
accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of
any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in
writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.12. Entire Agreement. This Agreement (including the Exhibits hereto) and the other Transaction Agreements constitute the full and
entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled. 

[Remainder of Page Intentionally Left Blank] 

  
 10 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the
date first written above. 
  

									
	NANTCELL, INC	 		 	NANTBIO, INC
					
	By:	 	 /s/ Charles Kim
	 		 	By:	 	 /s/ Charles Kim

					
	Name:	 	 Charles Kim
	 		 	Name:	 	 Charles Kim

		 	(print)	 		 		 	(print)
					
	Title:	 	 General Counsel
	 		 	Title:	 	 General Counsel

 

									
	 Address:
	 	 9920 Jefferson Boulevard
 Culver City, CA
90232
	 		 	 Address:
	 	 9920 Jefferson Boulevard
 Culver City, CA
90232EX-10.31

 Exhibit 10.31 

August 3, 2020 
 PERSONAL AND CONFIDENTIAL 

David Sachs 
 [***] 

 

	Re:	 Offer of Employment 

Dear David: 
 It gives me great pleasure to offer you the
position of Chief Financial Officer. I hope that you find working at ImmunityBio, Inc. (the “Company”) a richly rewarding experience. 

The offer is as follows: 
  

	1.	 Location: Your principal place of employment will be at the Company’s office at 2040 East Mariposa
Ave, El Segundo, CA 90245 

  

	2.	 Start Date: August 3, 2020 (the “Effective Date”). 

 

	3.	 Reporting To: Dr. Patrick Soon-Shiong – Chairman & CEO 

 

	4.	 Salary: As a salaried employee, you will receive an annual base salary of $387,000.00. The base
salary will be paid in accordance with the Company’s regularly established payroll practice. The base salary hereof is a gross amount, and the Company will be required to withhold from such amount deductions with respect to Federal, state and
local taxes, FICA, unemployment compensation taxes and similar taxes, assessments or withholding requirements. 

  

	5.	 Equity Compensation: The Company is in the process of designing and establishing an equity compensation
program, and you will be eligible to participate in that program consistent with your level of employment, tenure and other factors. The Company agrees that it will discuss and negotiate, in good faith, the award that will be granted to you under
the equity compensation program. Any such equity award or participation will also be subject to vesting and other terms and conditions, all as may be determined by the Company’s board of directors in its discretion. 

 

	6.	 Bonus Opportunity: You will be eligible to participate in the annual discretionary bonus plan for this
position. The discretionary target bonus is fifty percent (50%) of your base salary, and will be subject to such performance targets and other factors as may be determined in the sole discretion of the Company’s board of directors. You will
first be eligible to participate in the bonus plan for the 2020 calendar year (payable in 2021 and prorated for the partial year). As the annual bonus is subject to the attainment of

  
 9920 Jefferson Blvd.
Culver City, CA 90232 

	 	
performance targets, it may be paid at, above or below target levels. In order to receive any bonus payment, you must remain continuously employed through, and still be employed by the Company
on, the date any such bonus is paid. An employee earns a bonus only if he is employed on payment day and has not indicated an intent to resign. 

  

	7.	 Severance: In the event that the Company terminates your employment without Cause or you resign for Good
Reason, the Company shall pay you a single cash payment equal to (i) 83.33% of your then-current annual base salary (i.e., 10 months of severance) plus (ii) a prorated bonus paid out at 100% of your target annual bonus (i.e., the target 50%
bonus) for the calendar year in which such termination occurs (with the proration based on the number of whole months of employment during the calendar year in which the termination has occurred), less all applicable federal, state and local
withholdings and deductions; provided, that you will not be entitled to any such severance payment unless you execute and return to the Company a general release in favor of, and in a form satisfactory to, the Company and you do not revoke such
release during any applicable revocation period prescribed by law, and such release becomes effective within 60 days following your termination date. By way of example, if you get terminated without Cause after six (6) full months of
employment, then the Company shall pay you a single cash payment equal to 83.33% of your then-current annual base salary plus 25% of your then-current annual base salary (i.e., 50%, representing 6 full months of service, of your full 50% target
bonus). For the avoidance of doubt, and notwithstanding anything herein to the contrary, you will not be entitled to any severance payment if (a) the Company terminates your employment for Cause, (b) you resign or otherwise terminate your
employment with the Company other than for Good Reason, (c) your employment is terminated by reason of your death or Disability. The Company shall make any such severance payment on the 60th day following the date on which termination occurs,
subject to any required delay to satisfy the requirements of Section 409(A) as provided below. 

 For purposes of this
letter, the term “Cause” shall mean any of the following: (a) your material breach of any agreement with the Company, including the Employee Confidentiality and Invention Assignment Agreement, or any policy of the Company, which
breach has not been cured within twenty (20) days following written notice to you thereof; (b) your conviction of a felony or any other crime involving dishonesty, breach of trust, moral turpitude, or physical harm to any person (including
the Company or any of its employees); (c) your act of fraud, misconduct, intentional misrepresentation or dishonesty in connection with your duties or otherwise with the business of the Company; (d) your material breach in the performance of
your duties, including insubordination or excessive tardiness, or failure to implement or follow a lawful policy or directive of the Company, in each case where such failure is not cured within twenty (20) days following written notice to you
thereof; (e) your commission of any act or omission of gross negligence or willful misconduct in the performance of your duties; or (f) you being under the influence of alcohol or non-prescription
drugs, during work activities, except that “Cause” shall not include your proper use of prescription drugs with a valid prescription or proper use of
over-the-counter medications in accordance with the manufacturer’s recommendations or a physician’s directions or your modest consumption of alcohol during
business dinners or other work-related social events. For the purposes of this letter “Good Reason” shall mean a reduction in your base salary or target bonus percentage, without your written consent. Your voluntary termination shall be
deemed for purposes of this offer letter to have occurred for Good Reason only if (i) you provide written notice to the Company prior to 

  
 9920 Jefferson Blvd.
Culver City, CA 90232 

 
resignation and within thirty (30) days after you become aware of the circumstances giving rise to Good Reason, (ii) the Company fails to correct the circumstances giving rise to Good
Reason prior to resignation and within thirty (30) days following receipt of such notice and (iii) you resign within thirty (30) days following such thirty (30) day period.    For purposes of this letter,
“Disability” shall mean (i) you become eligible for the Company’s long-term disability benefits or (ii) in the reasonable opinion of the Company, you have been unable to carry out the essential responsibilities and functions
of your position by reason of any physical or mental impairment, with or without any reasonable accommodation, for more than ninety (90) consecutive days or more than one hundred twenty (120) days in any twelve (12) month period. 

To the extent necessary to comply with Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”)
(relating to payments made to certain “key employees” of certain publicly-traded companies), any severance payments payable under the terms of this letter which constitute deferred compensation subject to Code Section 409A to which
you would otherwise be entitled during the six (6) month period immediately following your separation from service will be paid on the earlier of (i) the first business day following the expiration of such six (6) month period or
(ii) your death. The Company and you agree that they will reasonably cooperate with each other to avoid the imposition of any additional taxes, interest and/or penalty under Section 409A of the Code. 

 

	8.	 Benefits: You will be eligible to participate in the benefits plans and programs that have been
established and/or may be adopted by the Company to the same extent as, and subject to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure (it being acknowledged and agreed that the
Company may, in its sole and absolute discretion, terminate at any time or modify from time to time any such benefit plans). 

  

	9.	 Vacation: As a regular full-time exempt employee, you are eligible to participate in an unlimited paid
time off program: employees have the authority to use their judgment and discretion and take temporary periods of time away from work as vacation, without loss of pay, as their work permits. 

 

	10.	 Eligibility to Work: On the Effective Date, you must present verification that you are eligible to be
employed in the United States as required by law. 

  

	11.	 Prior Agreements: You represent that you have full authority to enter into this Agreement and you are
not under any contractual restraint, which would prohibit you from satisfactorily performing your duties to the Company under this Agreement. Prior to the Effective Date, you must submit to the Company any confidential or other employment agreements
that you may have with your current or former employer. 

  

	12.	 Company Policies: You will be required to adhere to all Company policies and procedures as set forth in
the Employee Handbook, the Code of Business Conduct and as otherwise implemented from time to time. 

  

	13.	 Confidentiality Agreement: Prior to the Effective Date, you must execute a Proprietary Information and
Invention Assignment (the “Confidentiality Agreement”). 

  
 9920 Jefferson Blvd.
Culver City, CA 90232 

	14.	 Arbitration: Except for claims for equitable relief, you hereby agree that any and all disputes,
controversies and claims arising out of your employment and/or cessation of employment with the Company or otherwise relating to or connected with this offer letter shall be resolved exclusively through confidential, binding arbitration before a
single arbitrator and administered by the American Arbitration Association in accordance with its then existing Employment Arbitration Rules & Procedures. Such arbitration shall take place in Los Angeles, CA unless another venue is mutually
selected by you and the Company. All arbitration awards shall be final, conclusive and binding upon you and the Company, and any judgment upon such an award may be entered and enforced in any court of competent jurisdiction located in
CALIFORNIA or otherwise. You hereby waive your right to have any dispute resolved in a court of law by a judge or jury. 

  

	15.	 Employment At Will: This offer is for EMPLOYMENT AT WILL such that your employment with the Company can
be terminated by either you or the Company at any time, for any reason or no reason, with or without cause and with or without prior notice. In addition, the Company may alter the terms of employment at any time, in its sole discretion, subject to
Section 7. 

  

	16.	 Full Agreement: It is understood, acknowledged and agreed that there are no oral agreements between the
parties hereto or their affiliates and that this offer letter constitutes the parties’ and their affiliates’ entire agreement and supersedes and cancels any and all previous negotiations, arrangements, agreements and understandings, if
any, between the parties hereto and their affiliates, and none thereof shall be used to interpret or construe this offer letter. This offer letter and the Confidentiality Agreement contain all of the terms, covenants, conditions, warranties and
agreements of the parties shall be considered to be the only agreement between the parties hereto and their respective representatives and agents with respect thereto. This offer letter may be amended, superseded or otherwise modified only by a
written instrument executed by you and an officer of the Company. 

  

	17.	 Expiration of Offer: If this offer is not accepted by August 3, 2020, it will
be considered automatically withdrawn and no longer valid. We look forward to you joining our organization. If you should have any questions, please contact me at 310.853.7585. 

 

	
	Sincerely,
	
	 /s/ Stephen Horn

	Stephen Horn
	Human Resources – Talent Acquisition Manager

 cc: Personnel File 
 My
signature indicates acceptance of this offer: 
  

	
	 /s/ David Sachs

	David Sachs

  
 9920 Jefferson Blvd.
Culver City, CA 90232

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]